Clinical Trials for Relapsing MS

Clinical Trials for Patients with Relapsing Multiple Sclerosis

* indicates studies open for enrollment

Biogen 109MS303 BG12 ENDORSE
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis

* Genentech MN30035 CHORDS
Open-label study to evaluate the effectiveness and safety of Ocrelizumab in patients with RRMS who have had a suboptimal response to an adequate course of disease-modifying treatment

*Genentech MA30143 ENSEMBLE
Open-label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage RRMS

Genzyme CAMMS03409 Campath Extension Study
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of Alemtuzumab (Protocol # CAMMS03409; also known as the CARE-MSSM Extension Study)

Genzyme LPS13649 TOPAZ
Multicenter, open-label, concomparative study to evaluate the long-term safety, efficacy and self-reported quality of life of Alemtuzumab in patients who have completed at least 48 months of the extension study CAMMS03409

Roche WA21093 OPERA
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Observational Trials for Patients with Relapsing Multiple Sclerosis

All patients starting Tecfidera, Plegridy and Gilenya are asked to participate in the below Phase IV observational clinical trials.

* Biogen 109MS401 ESTEEM
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)Additional information on this clinical trial can be found here.

*Genzyme TeriMOOD (OBS14501): A prospective, noninterventional, observational study designed to evaluate depressed mood in patients with relapsing forms of multiple sclerosis who have recently switched from interferon therapy to Aubagio 14mg due to symptoms of depression.

*Genzyme IVSS (OBS14379): A prospective observational cohort study in adult patients with relapsing multiple sclerosis to further characterize the safety profile of Lemtrada by vital sign monitoring during and after all infusions comprising the first treatment course.

* Novartis FTY2403 PASSAGE
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapyAdditional information on this clinical trial can be found here.

Novartis FTY2405 TRANSITION
A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod
Additional information on this clinical trial can be found here.